NGEN:CC News and Press, Nervgen Pharma Corp. From 03/21/24

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ VANCOUVER, BC , March 21, 2024 /CNW/ - NervGen Pharma Corp. (" NervGen " ...

Canadian Investment Regulatory Organization Trading Halt - NGEN Canada NewsWire VANCOUVER, BC , March 21, 2024 /CNW/ - The following issues have been halted by CIRO Company: NervGen Pharma Corp. TSX-Venture Symbol: NGEN All Issues: Yes Reason: Pending...

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 20...

On track to complete enrollment of the chronic cohort in Q2 2024 Data readout from chronic cohort expected in Q3 2024 Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - ...

2024-02-13 16:10:00 ET The healthcare sector in Canada is quite diverse, even if we exclude the cannabis stocks from this list. It includes biotech companies that may offer explosive growth potential with the right breakthrough and senior care businesses that may offer reliable inco...

Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Seasoned financial industry execut...

Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech compan...

Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024 Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) -   NervGe...

Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen's board Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 under...

Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) , a clinical stage biotech compa...